The average one-year price target for Xenon Pharmaceuticals (NasdaqGM:XENE) has been revised to $80.01 per share, an increase of 41.64% from the previous estimate of $56.49 on February 21, 2026. The new target range spans from a low of $50.50 to a high of $105.00 per share, representing an increase of 44.04% from the last reported closing price of $55.55.
As of the latest reporting, 288 funds hold positions in Xenon Pharmaceuticals, a decrease of 33.79% from the previous quarter. Institutional ownership dropped by 15.26% to 85,125K shares. The put/call ratio for XENE stands at 1.16, indicating a bearish sentiment among investors. Notable shareholders include Avoro Capital Advisors with 5,424K shares (5.68% ownership) and Wellington Management Group LLP with 4,765K shares (4.99% ownership), both firms adjusting their portfolio allocations in XENE over the last quarter.
